Collegium Pharmaceutical

Yahoo Finance • 13 days ago

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 – –... Full story

Yahoo Finance • last month

Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment

Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking ahead, the branded pharmaceutical industry is positioned for tailwinds from adva... Full story

Yahoo Finance • last month

3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly... Full story

Yahoo Finance • 2 months ago

Is Collegium Pharmaceutical (COLL) One of the Best Small-Cap Drug Manufacturers

Collegium Pharmaceutical Inc. (NASDAQ:COLL) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On March 24, Vikram Karnani, President and CEO at Collegium Pharmaceutical Inc. (NASDAQ:COLL), shared hi... Full story

Yahoo Finance • 2 months ago

Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million

Scott Dreyer, Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical(NASDAQ:COLL), reported the sale of 49,976 shares of common stock in open-market transactions on March 3, 2026, according to an SEC Form 4 filin... Full story

Yahoo Finance • 2 months ago

Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037

Collegium Pharmaceutical logo 5 Hot Stocks With Summer Buybacks You Can Cash In On Collegium Pharmaceutical (NASDAQ:COLL) outlined plans to acquire the ADHD drug AZSTARYS and related corporate subsidiaries from Corium Therapeutics, a tra... Full story

Yahoo Finance • 2 months ago

Collegium Strengthens ADHD Portfolio With AZSTARYS Acquisition

(RTTNews) - Collegium Pharmaceutical, Inc. (COLL) has announced a definitive agreement to acquire AZSTARYS from Corium Therapeutics for $650 million in cash, with potential milestone payments up to $135 million. The acquisition adds a dif... Full story

Yahoo Finance • 2 months ago

Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory

– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYSExpected to Generate Over $50 Million... Full story

Yahoo Finance • 2 months ago

BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health Shares Are Soaring, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. The retreat in oil prices provided temporary relief to a market that was volatil... Full story

Yahoo Finance • 2 months ago

Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference

Collegium Pharmaceutical logo Key Points Collegium reported a “record-breaking” 2025 with strong net revenue and adjusted EBITDA performance, led by JORNAY PM which grew 48.9% YoY driven by ~20% volume growth, expanded salesforce (125→18... Full story

Yahoo Finance • 2 months ago

3 Healthcare Stocks Walking a Fine Line

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 3.8%... Full story

Yahoo Finance • 3 months ago

Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results

Third Avenue Management, a New York City-based investment firm, published its fourth-quarter 2025 investor letter for the “Third Avenue Small-Cap Value Fund. " A copy of the letter is available for download here. In the quarter, the Fund r... Full story

Yahoo Finance • 3 months ago

Collegium Pharmaceutical Q4 Earnings Call Highlights

Collegium Pharmaceutical logo Key Points Record 2025 results and stronger balance sheet: Collegium reported full-year net revenues of $780.6 million and adjusted EBITDA of $460.5 million, generated over $329 million of cash from operatio... Full story

Yahoo Finance • 3 months ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * Vistance Networks (VISN [https://seekingalpha.com/symbol/VI... Full story

Yahoo Finance • 3 months ago

Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds.Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio Collegium P... Full story

Yahoo Finance • 7 months ago

Collegium anticipates 24% revenue growth in 2025 with Jornay PM driving expansion

Earnings Call Insights: Collegium Pharmaceutical (COLL) Q3 2025 MANAGEMENT VIEW * CEO Vikram Karnani reported continued top and bottom line growth, citing a strong back-to-school season for Jornay PM and robust pain portfolio revenues.... Full story

Yahoo Finance • 7 months ago

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

– Generated Record Quarterly Net Revenue of $209.4 Million,Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portf... Full story

Yahoo Finance • 7 months ago

Knight Therapeutics Announces Launch of JORNAY PM™ in Canada

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™ (methylphenidate HCI extended-release capsules... Full story

Yahoo Finance • 7 months ago

Thérapeutique Knight annonce le lancement de JORNAY PM(MC) au Canada

MONTRÉAL, 30 oct. 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc., (TSX : GUD) (« Knight »), société pharmaceutique panaméricaine (hors États-Unis) spécialisée, a annoncé aujourd’hui le lancement de JORNAY PMMC (capsules à libération... Full story

Yahoo Finance • 7 months ago

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

Collegium Pharmaceutical, Inc. – Collegium to Ring Nasdaq Opening Bell on October 14, 2025 – STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management team will... Full story